Mitral Valve prolapse: What s new? Which indications of early surgery? Input of new 2017 ESC/EACTS guidelines. Christophe Tribouilloy Amiens, France

Similar documents
Chronic Primary Mitral Regurgitation

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017

Primary Mitral Regurgitation

What is the Role of Surgical Repair in 2012

Les valvulopathies en sourdine: la valve mitrale Quoi faire devant une régurgitation mitrale sévère asymptomatique de type dégénérative?

Advanced Evaluation of Left Ventricular Function in Degenerative MR. Dr Julien Magne, PhD University of Liege, CHU Sart Tilman, Liege, Belgium

How does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? NO DISCLOSURE

Valvular Guidelines: The Past, the Present, the Future

Assessing Function by Echocardiography in VHD Asymptomatic Severe Organic MR. Dr. Julien Magne, PhD Sart Tilman Liège, BELGIUM

Asymptomatic Valvular Disease:

Exercise Pulmonary Hypertension predicts the Occurrence of Symptoms in Asymptomatic Degenerative Mitral Regurgitation

Επιδιόπθωζη μιηποειδικήρ ζςζκεςήρ ζε ππόπηωζη ή πήξη γλωσίνων. Βαζίλειορ Σασπεκίδηρ Επιμεληηήρ Β Καπδιολογίαρ Γ.Ν. Παπαγεωπγίος

DECISION MAKING DEL CARDIOCHIRURGO NELL INSUFFICIENZA MITRALICA: ISTRUZIONI D USO D CARDIOLOGO

Severe left ventricular dysfunction and valvular heart disease: should we operate?

Exercise PHT in valvular heart disease. Julien Magne CHU Limoges, France

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan

Organic mitral regurgitation

Load and Function - Valvular Heart Disease. Tom Marwick, Cardiovascular Imaging Cleveland Clinic

Low Gradient Severe? AS

Clinical Outcome of Tricuspid Regurgitation. David Messika-Zeitoun

I have financial relationships to disclose Honoraria from: Edwards

Late secondary TR after left sided heart disease correction: is it predictibale and preventable

Quality Outcomes Mitral Valve Repair

Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid

J Cardiovasc Med 2012, 13: Received 19 October 2011 Revised 8 November 2011 Accepted 29 November 2011

Spotlight on Valvular Heart Disease Guidelines

Transcatheter Echo Guided Mitral Valve Repair with NeoChord Implantation: Results from NeoChord Independent International Registry

Natural History and Echo Evaluation of Aortic Stenosis

Severe aortic stenosis should be operated before symptom onset CONTRA. Helmut Baumgartner

Ann Thorac Cardiovasc Surg 2015; 21: Online April 18, 2014 doi: /atcs.oa Original Article

Mitral Regurgitation

Prognostic Impact of FMR

Catheter-based mitral valve repair MitraClip System

Mitral Valve Prolapse and Sudden Death. JF Avierinos Hôpital Timone Marseille January 27th, 2017

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

The difficult patient with mitral regurgitation

«Paradoxical» low-flow, low-gradient AS with preserved LV function: A Silent Killer

Exercise Testing/Echocardiography in Asymptomatic AS

Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F.

A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision

Evaluation of the Right Ventricle and Risk Stratification for Sudden Cardiac Death

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL

Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome

Pulmonary Hypertension: Follow-up in adolescence and adults

Interventional solutions for atrial fibrillation in patients with heart failure

Candice Silversides, MD Toronto Congenital Cardiac Centre for Adults University of Toronto Toronto, Canada

Latest therapies for patients with HF. Dr AIGUL BALTABAEVA PhD, FESC, FRCP RBHT & ASPH

NeoChord Mitral Valve Repair. Department of Cardiac, Thoracic and Vascular Sciences University of Padua, Italy

Steven F Bolling Professor of Cardiac Surgery University of Michigan

Gonçalo F. Coutinho, Ana Luís Garcia, Pedro M. Correia, Carlos Branco and Manuel J. Antunes*

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines

ECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction

Echocardiographic Correlates of Pulmonary Artery Systolic Pressure

Minimally Invasive Mitral Valve Repair: Indications and Approach

Management of significant asymptomatic aortic stenosis. Alec Vahanian Bichat Hospital University Paris VII Paris, France

Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας

Risk stratification of severe aortic stenosis according to new guidelines: long term outcomes

The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD

Aortic stenosis with concomitant mitral regurgitation

Survival Implication of Left Ventricular End-Systolic Diameter in Mitral Regurgitation Due to Flail Leaflets

2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease

Management of the Female Pa4ent with a Cardiac Murmur

Evaluation of Left Ventricular Diastolic Dysfunction by Doppler and 2D Speckle-tracking Imaging in Patients with Primary Pulmonary Hypertension

Heart Failure with preserved ejection fraction (HFpEF)

How atrial fibrillation should be treated in the heart failure patient?

Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro

Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?

Valvular Regurgitation: Can We Do Better Than Colour Doppler?

Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain

Disclosures. ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know

ECHOCARDIOGRAPHY DATA REPORT FORM

Functional Mitral Regurgitation

Highlights from EuroEcho 2009 Echo in cardiomyopathies

Atrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction

Surgical Approach To Functional MR: One Size Does Not Fit All

ESC / EACTS new valvular guidelines- Update

What Degree of MR Deserves Surgical or Transcatheter Intervention, and How Should It Be Assessed?

Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S.

When is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII

Imaging in dilated cardiomyopathy : factors associated with a poor outcome

Τελικά επιδιόρθωση, αντικατάσταση ή clip στην ισχαιμική ανεπάρκεια Μιτροειδούς; ΒΛΑΣΗΣ ΝΙΝΙΟΣ MD MRCP ΚΛΙΝΙΚΗ ΑΓΙΟΣ ΛΟΥΚΑΣ

Tetralogy of Fallot Latest data in risk stratification and replacement of pulmonic valve

Bogdan A. Popescu. University of Medicine and Pharmacy Bucharest, Romania. EAE Course, Bucharest, April 2010

DICE Session. The endocarditis team. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France

ABLATION OF CHRONIC AF

Indicator Mild Moderate Severe

Percutaneous Mitral Valve Repair

Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

CARDIOLOGY GRAND ROUNDS

Which Type of Secondary Tricuspid Regurgitation Accompanying Mitral Valve Disease Should Be Surgically Treated?

Secondary Mitral Regurgitation: When Should We Intervene?

What echo measurements are key prior to MitraClip?

Clinical Practice Guidelines and the Under Treatment of Concomitant AF Vinay Badhwar, MD

Role of Stress Echo in Valvular Heart Disease. Satoshi Nakatani Osaka University Graduate School of Medicine Osaka, Japan

Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France

Cases of mitral valve causing mitral regurgitation: the MV prolapse spectrum CASE

Transcription:

Mitral Valve prolapse: What s new? Which indications of early surgery? Input of new 2017 ESC/EACTS guidelines Christophe Tribouilloy Amiens, France

I have no financial relationships to disclose related to this presentation.

ESC/ EACTS September 2017

50 yo, male with MR

Primary Mitral Regurgitation Post-operative LVD after valve repair Series pre-op EF late post-op EF post-oplv (%) (%) Dysfunction Leung 1996 64 55 24% Tribouilloy 2011 68 59 16% Witkowski 2013 66 61 12% Repair reduces the rate of post-op LVD compared to MV replacement but does not suppress post-op LVD

Asymptomatic MR : Operative Mortality is Low Operative Mortality (%) Tribouilloy et al Circulation 1999 15 10 5 0 5.4% 12.7% 2.5% Severe symptoms (class III-IV) 0.5% 3.6% Overall 75 <75 0 No or minimal symptoms (class I-II)

MR Postoperative Outcome Long-term Survival 100 80 P<0.0001 P=0.18 % 60 40 Observed Expected 20 0 NYHA III-IV 0 2 4 6 8 10 Years NYHA I-II 0 2 4 6 8 10 Years Tribouilloy et al Circulation 1999

Asymptomatic Severe MR due to MV prolapse The essential questions Is the patient really asymptomatic? Is MR really severe? Can valve repair be performed? What are the repercussions of MR on LV and LA? What are the repercussions of MR on PAP? Does the patient have AF? What are the patient s wishes Does the expected benefits of intervention (versus spontaneous outcome) outweigh its risks?

ERO 0.42 cm², RV 64 ml Is MR really severe?

Survival, % Asymptomatic MR: Natural History (n=456; EF > 50%) 100 91±3 % 90 80 70 60 50 66±6 % P<0.01 ERO 1-19 mm2 ERO 20-39 mm2 ERO 40 mm2 58±9 % 0 1 2 3 4 5 Years Enriquez Sarano et al NEJM 2005

Can valve repair be performed?

Lazam et al Circulation 2017

Mitral valve repair improves surgical result Lazam et al Circulation 2017

Mitral Valve Repair ESC / EACTS 2017

What are the repercussions of MR on LV function? MR due to Flail Leaflets Mortality on conservative management according to EF Tribouilloy et al Circ Cardiovasc Imaging 2014

What are the repercussions of MR on LV function? MR due to Flail Leaflets Long-term survival according to LV-ESD n=739 Cut-off: 40mm or 22 mm/m² HR: 1.95 overall mortality, HR: 3 CV mortality Tribouilloy et al JACC 2009

Mitral Valve Prolapse Echocardiographic prediction of LVD after MV repair Tribouilloy et al Eur J of Echocardiography 2011

What are the repercussions of MR on Left Atrial? MR due to Flail Leaflets Long-term survival according to LA diameter/volume 100% 90±3% P < 0.0001 LA diam < 55mm LA diam >55mm P < 0.0001 LA-index < 40 ml/m² LA-index 40-59 ml/m² LA-index 60 ml/m² 84±5% 53±9% 1 2 3 4 5 Years Rusinaru et al Circulation Imaging 2011 Letourneau et al JACC 2010

ESC / EACTS 2017

Overall Survival, % 100 Does the patient have atrial fibrillation? Preoperative AF: A key determinant of outcome in severe MR due to mitral valve prolapse 90 80 70 60 50 40 83±3% 70±6% 59±6% SINUS RHYTHM PAROXYSMAL AF PERMANENT AF 30 20 10 0 p<0.0001 0 2 4 6 8 10 years Szymanski et al Am J cardiol 2015

What are the repercussions of MR on PAP? MR due to Flail Leaflets Long-term survival according to PAP Survival according to rest systolic PAP Survival according to rest pre-operative systolic PAP n= 437 PH: Syst. PAP > 50mmHg Barbieri et al, Eur Heart J 2010 Le Tourneau, Heart 2010; 96:1311-1317

Right catheterism ESC / EACTS 2017

ESC / EACTS 2017 PH during exercise > 60mmHg ESC 2017 guidelines: no recommandation for surgery in primary MR based on exercise echocardiography Magne et al Circulation 2010 Class II B

EF > 60% End point = CHF, left ventricular dysfunction (EF<60%) or death ESC 2017 guidelines: «low plasma BNP has a high negative predictive value as predictor of symptom onset and may be helpful in the follow-up of asymptomatic patients»

Global longitudinal strain (GLS) Asymptomatic MR due to MVP with preserved EF (n=135) N=135 ESC 2017 guidelines: «global longitudinal strain could be of potential interest for the detection of subclinical LV dysfunction» Cardiac event-free survival stratified according to median global longitudinal strain ( 20%) Magne et al Heart 2012; 98: 584

Chronic MR due to mitral valve prolapse Higher rate of events on conservative management in pts with absence of increase of GLS of 2% or more. left ventricular EF global longitudinal strain Δ EF < 4 % Δ GLS < 2% Cardiac events: cv death, MV surgery, LV dysfunction Magne J et al. Eur Heart J 2014

Mitral Regurgitation due to MV Prolapse - Asymptomatic severe MR - High probability of valve repair - EF> 60% and ESD < 40mm - LA Volume < 60ml/m² - PAP < 50mm Hg (at rest) - Sinus rhythm - Low operative risk

Women, 71 yo, asymptomatic, 1.65m, 62 kg, FEVG 73% DTD 62 mm DTS 34 mm

AHA/ACC 2017: likelihood of successful and durable repair without residual MR >95% with an expected operative mortality < 1% when performed at a Heart valve center of excellence (recommandation class IIa; B) ESC 2017: Watchful waiting is a safe strategy in asymptomatic patients with severe ESC primary MR 2012/ and 2017 none with none of the above indications for surgery

Watchful Waiting in Asymptomatic Dystrophic MR Rosenhek et al Circulation 2006 Surgery : symptoms, atrial fibrillation, PAPS > 50mmHg, EF < 60%, ESD > 45 mm (or 26 mm/m²) 132 pts, 55 yo surgery in 35 pts, MV repair in 83%, no operative mortality LV dimensions EDD 56 ± 6 mm ESD 34 ± 5 mm

Asymptomatic Severe Mitral Regurgitation Events leading to surgery 100 90 80 70 60 50 40 30 20 10 0 0 1 2 3 4 5 6 7 8 Years new onset Afib/PHT asympt. LV-dysfunction symptoms any event Rosenhek et al. Circulation 2006;113:2238-2244.

Early surgery vs conservative treatment in asymptomatic severe degenerative MR Pts without LV dysfunction or dilatation, AF, PAH n=132 Effect of follow-up regularity and quality on outcome Early surgery defined as within 3 months of diagnosis 4 pts not operated despite class I or IIa indications Montant et al JTCVS 2009;1339

Prospective registry 610 pts, mean age 50 yo Kang et al JACC 2014

Asymptomatic Degenerative Severe MR Early Surgery vs Waiting for Symptoms A propensity analysis No significant difference in overall mortality Registry 610 pts, mean age 50 yo Excess cardiovascular mortality Kang et al JACC 2014

MR due to Flail leaflets: Early Surgery No heart failure symptoms, EF 60, LVESD<40mm Retrospective registry: - n=1021 without class I indication for surgery - Early surgery defined as within 3 months of diagnosis Suri al JAMA 2013;310:609

Survival in MR due to Flail Leaflets Early surgery versus initial medical management Propensity score matched cohort -pts without class I indication for surgery (n=1021) -22% with class IIa indication (AFib and/or PHT) Each patient in the conservative group had follow-up visits with a physician within each participating center or elsewhere HR 0.52, P< 0.03 Suri et al. JAMA 2013;310:609

CHF in severe MR due to Flail Leaflet Early surgery versus initial medical management HR 0.29, P< 0.01 HR 0.44, P< 0.03 Suri et al JAMA 2013

ESC EACTS 2017 Guidelines Etude REVERSE-MR (PHRC 2016) Randomized comparison of Early mitral ValvE Repair versus watchful waiting for asymptomatic SEvere degenerative Mitral Regurgitation due to leaflet prolapse.

Severe Asymptomatic Primary MR No Risk Factor Surgery delayed with regular FU Classical indications: -LV Dysfunction -AF -Pulm. hypertension Prompt surgery Risk factors LA 60 ml/m2 LVS 36-39 mm EF 60-64% SPAP 45-49 mmhg BNP activation -ERO > 40mm² -low operative risk -Valve repair (MVP) Early surgery